AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7821097 — intervention group
Group type: COMPARATOR
Intervention: Persistent Helicobacter pylori infection; N = 38
Number of subjects: 83
Study 7821097 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication of Helicobacter pylori infection; N = 37
Number of subjects: 83
Study 2295234 — intervention group
Group type: EXPERIMENTAL
Intervention: Pall Ultipor breathing circuit filter (PUBCF)
Number of subjects: 48
Study 2295234 — intervention group
Group type: COMPARATOR
Intervention: Heated hot water systems (HHWS)
Number of subjects: 48
Study 647178 — intervention group
Group type: EXPERIMENTAL
Intervention: 5F/week
Number of subjects: 687
Study 647178 — intervention group
Group type: COMPARATOR
Intervention: 3F/week
Number of subjects: 687
Study 31487608 — intervention group
Group type: EXPERIMENTAL
Intervention: CT optimal velocity stroking touch
Number of subjects: 0
Study 31487608 — intervention group
Group type: COMPARATOR
Intervention: Static touch
Number of subjects: 0
Study 29096591 — intervention group
Group type: EXPERIMENTAL
Intervention: Flipped classroom instruction (FG, n=48)
Number of subjects: 95
Study 29096591 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture-based instruction (TG, n=47)
Number of subjects: 95
Study 25112695 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine examination
Number of subjects: 110
Study 25112695 — intervention group
Group type: COMPARATOR
Intervention: In-person examination
Number of subjects: 110
Study 21770863 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype milk A
Number of subjects: 42
Study 21770863 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype milk B
Number of subjects: 42
Study 21770863 — intervention group
Group type: COMPARATOR
Intervention: Non-supplemented milk
Number of subjects: 42
Study 19602608 — intervention group
Group type: EXPERIMENTAL
Intervention: Icodextrin (ICO)
Number of subjects: 59
Study 19602608 — intervention group
Group type: COMPARATOR
Intervention: Glucose-based solutions (GLU)
Number of subjects: 59
Study 17879825 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE) at doses of 0.3, 0.625, and 1.25 mg for 3 months each, totaling 9 months of treatment.
Number of subjects: 9
Study 14693584 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine plus 1 micro g/kg clonidine
Number of subjects: 75
Study 14693584 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine alone (control group)
Number of subjects: 75
Study 14693584 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine plus 2 micro g/kg clonidine
Number of subjects: 75
Study 14693584 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine plus 0.25, 0.5 micro g/kg clonidine
Number of subjects: 75
Study 12359987 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with nitrendipine (with second- and third-line enalapril and hydrochlorothiazide)
Number of subjects: 610
Study 12359987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 610
Study 9841599 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin, 40 mg/d
Number of subjects: 1283
Study 9841599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1283
Study 8721722 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal polyps with fibrous connective core infiltrated by monocyte-macrophage lineage cells (mixed type)
Number of subjects: 22
Study 8721722 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal polyps with central oedematous connective tissue infiltrated by eosinophils (glandular and oedematous types)
Number of subjects: 22
Study 8721722 — intervention group
Group type: COMPARATOR
Intervention: Hypsilateral mucous membranes
Number of subjects: 22
Study 2654067 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 38
Study 2654067 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 38
Study 474640 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 7
Study 474640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 31744701 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconference group meetings (5 sessions, 1.5 hours each)
Number of subjects: 112
Study 31744701 — intervention group
Group type: COMPARATOR
Intervention: Remote monitoring only (control group)
Number of subjects: 112
Study 31744701 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconference group meetings
Number of subjects: 112
Study 31152874 — intervention group
Group type: EXPERIMENTAL
Intervention: AVATAR protocol cryoballoon ablation without assessment of acute PV isolation or overnight hospitalization
Number of subjects: 321
Study 31152874 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy with anti-arrhythmic drugs
Number of subjects: 321
Study 31152874 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional cryoballoon ablation with assessment of acute PV isolation
Number of subjects: 321
Study 27117011 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip brace
Number of subjects: 14
Study 27117011 — intervention group
Group type: COMPARATOR
Intervention: Unbraced (control)
Number of subjects: 14
Study 25319932 — intervention group
Group type: EXPERIMENTAL
Intervention: Poly-L-lactic acid (PLA) filler
Number of subjects: 0
Study 25319932 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid (HA) filler
Number of subjects: 0
Study 24106804 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 30-70 mg/d
Number of subjects: 161
Study 24106804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 21371988 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive arm offered a £5 Amazon.co.uk gift voucher, a £5 charity donation to Cancer Research UK, or entry in a prize draw for £250 (study 1)
Number of subjects: 3817
Study 21371988 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive arm offered a £10 Amazon.co.uk gift voucher (study 2)
Number of subjects: 3817
Study 19349547 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(3) (cholecalciferol) 400 IU and calcium carbonate 1,000 mg daily for 1 year
Number of subjects: 103
Study 17242259 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast harmonic sonography-guided radiofrequency ablation
Number of subjects: 40
Study 17242259 — intervention group
Group type: COMPARATOR
Intervention: B-mode sonography
Number of subjects: 40
Study 17064323 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity-based nursing intervention
Number of subjects: 0
Study 17064323 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (non-intervention)
Number of subjects: 0
Study 12560886 — intervention group
Group type: EXPERIMENTAL
Intervention: HA bone cement injected into the vertebral body through curetted pedicles using specially designed needles
Number of subjects: 9
Study 12560886 — intervention group
Group type: COMPARATOR
Intervention: Cement injected using 16‐gauge Ostycut biopsy needles via the pedicles
Number of subjects: 9
Study 10098807 — intervention group
Group type: EXPERIMENTAL
Intervention: In-car enforcement and tutoring system; auditory and visual tutoring messages provided when deviations from normative behaviour were detected.
Number of subjects: 0
Study 10098807 — intervention group
Group type: EXPERIMENTAL
Intervention: In-car enforcement and tutoring system; feedback conditions.
Number of subjects: 0
Study 8904578 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm below heart position at 2.2 W
Number of subjects: 10
Study 8904578 — intervention group
Group type: COMPARATOR
Intervention: Arm above heart position at 2.2 W
Number of subjects: 10
Study 8904578 — intervention group
Group type: COMPARATOR
Intervention: Arm above heart position
Number of subjects: 10
Study 8904578 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm below heart position at 1.4 W
Number of subjects: 10
Study 2007924 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein hydrolysate formula (Alimentum)
Number of subjects: 25
Study 2007924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 2007924 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow milk (10 gm powdered)
Number of subjects: 25
Study 7064903 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk
Number of subjects: 28
Study 7064903 — intervention group
Group type: COMPARATOR
Intervention: Proprietary formula
Number of subjects: 28
Study 31825141 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFIRI (irinotecan, 5‐fluorouracil and leucovorin)
Number of subjects: 128
Study 31825141 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX7 (oxaliplatin, 5‐fluorouracil and leucovorin)
Number of subjects: 128
Study 31095602 — intervention group
Group type: EXPERIMENTAL
Intervention: MRCI-K (Korean version of the medication regimen complexity index)
Number of subjects: 335
Study 31095602 — intervention group
Group type: COMPARATOR
Intervention: Expert panel evaluation
Number of subjects: 335
Study 27623161 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper Body Compression Garment (UBCG)
Number of subjects: 12
Study 27623161 — intervention group
Group type: COMPARATOR
Intervention: Control garment
Number of subjects: 12
Study 25951857 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 2 mg, 5 mg, or 15 mg, twice daily for 12 weeks
Number of subjects: 0
Study 25951857 — intervention group
Group type: COMPARATOR
Intervention: Placebo, twice daily for 12 weeks
Number of subjects: 0
Study 24140677 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) cohort
Number of subjects: 1800
Study 24140677 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass graft (CABG) cohort
Number of subjects: 1800
Study 21390339 — intervention group
Group type: EXPERIMENTAL
Intervention: Short axis ultrasound guided cannulation
Number of subjects: 99
Study 21390339 — intervention group
Group type: COMPARATOR
Intervention: Long axis ultrasound guided cannulation
Number of subjects: 99
Study 18952347 — intervention group
Group type: EXPERIMENTAL
Intervention: LTS-D
Number of subjects: 200
Study 18952347 — intervention group
Group type: COMPARATOR
Intervention: I-gel
Number of subjects: 200
Study 17373900 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (humanised monoclonal antibody to the HER2 receptor)
Number of subjects: 0
Study 17373900 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy and endocrine therapies
Number of subjects: 0
Study 15292325 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg daily for nine months
Number of subjects: 10
Study 15292325 — intervention group
Group type: COMPARATOR
Intervention: Control data (not specified)
Number of subjects: 10
Study 11903176 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital luminescence radiography (DLR)
Number of subjects: 210
Study 11903176 — intervention group
Group type: COMPARATOR
Intervention: Conventional film screen radiography
Number of subjects: 210
Study 11903176 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DLR and conventional film screen radiography
Number of subjects: 210
Study 9034949 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐administered, structured, previsit questionnaire combined with a postvisit questionnaire
Number of subjects: 318
Study 9034949 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviewer‐administered, semistructured, previsit interview combined with a postvisit questionnaire
Number of subjects: 318
Study 9034949 — intervention group
Group type: COMPARATOR
Intervention: Postvisit questionnaire only
Number of subjects: 318
Study 8201487 — intervention group
Group type: EXPERIMENTAL
Intervention: Beractant (Survanta)
Number of subjects: 1228
Study 3661954 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 0.5 micrograms/kg
Number of subjects: 40
Study 3661954 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 1.0 micrograms/kg
Number of subjects: 40
Study 3661954 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 2.0 micrograms/kg
Number of subjects: 40
Study 3661954 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pindolol)
Number of subjects: 40
Study 31837032 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message sent after donation
Number of subjects: 20365
Study 31837032 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message sent in the evening
Number of subjects: 20365
Study 31837032 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message effect on whole blood donors
Number of subjects: 20365
Study 31837032 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message effect on plasma donors
Number of subjects: 20365
Study 31328432 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted reproductive technologies (ART) and non-IVF fertility treatments (NIFTs)
Number of subjects: 159
Study 31328432 — intervention group
Group type: COMPARATOR
Intervention: Control group (infants with PVD but without ART/NIFT)
Number of subjects: 159
Study 27999970 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 30% glucose solution (2 ml/3 kg doses)
Number of subjects: 112
Study 27999970 — intervention group
Group type: COMPARATOR
Intervention: Intravenous midazolam (0.1 mg/kg with 0.05 mg/kg repetition)
Number of subjects: 112
Study 26356162 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin (intravenously in dose 20 ml in 100 ml of physiological solution, 5 days a week, during 4 weeks)
Number of subjects: 60
Study 26356162 — intervention group
Group type: COMPARATOR
Intervention: Standard neurorehabilitation measures
Number of subjects: 60
Study 23368405 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 208
Study 23368405 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 208
Study 20488830 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g glucose
Number of subjects: 30
Study 20488830 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g glucose
Number of subjects: 30
Study 20488830 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g glucose
Number of subjects: 30
Study 20488830 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 g glucose
Number of subjects: 30
Study 20488830 — intervention group
Group type: COMPARATOR
Intervention: 0 g glucose
Number of subjects: 30
Study 19474688 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 1066
Study 19474688 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 1066
Study 19474688 — intervention group
Group type: COMPARATOR
Intervention: Bisoprolol-Control
Number of subjects: 1066
Study 19474688 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin-Control
Number of subjects: 1066
Study 16959149 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (Group A)
Number of subjects: 600
Study 16959149 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid replacement only (Group B)
Number of subjects: 600
Study 16959149 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Group C)
Number of subjects: 600
Study 15040556 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 0
Study 15040556 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphadoxine‐pyrimethamine (SP)
Number of subjects: 0
Study 15040556 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 0
Study 15040556 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine + Sulphadoxine‐pyrimethamine (AQ + SP)
Number of subjects: 0
Study 15040556 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate + Sulphadoxine‐pyrimethamine (AR + SP)
Number of subjects: 0
Study 15040556 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine + Artesunate (AQ + AR)
Number of subjects: 0
Study 15040556 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapies (AQ + SP, AR + SP, AQ + AR)
Number of subjects: 0
Study 12194076 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% (w/v) sodium hyaluronate (HA)
Number of subjects: 39
Study 12194076 — intervention group
Group type: COMPARATOR
Intervention: 1.4% (w/v) polyvinyl alcohol
Number of subjects: 39
Study 9476988 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana with long breath-holding duration
Number of subjects: 55
Study 9476988 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana with short breath-holding duration
Number of subjects: 55
Study 9476988 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana
Number of subjects: 55
Study 9476988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 9476988 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath-holding duration (long vs short)
Number of subjects: 55
Study 8585876 — intervention group
Group type: EXPERIMENTAL
Intervention: Amtolmetineguacil 600 mg by os twice daily for the first two days followed by 600 mg once daily for 19 days (Group A1)
Number of subjects: 30
Study 8585876 — intervention group
Group type: EXPERIMENTAL
Intervention: Amtolmetineguacil 600 mg twice daily for 21 days (Group A2)
Number of subjects: 30
Study 8585876 — intervention group
Group type: COMPARATOR
Intervention: diclofenac 50 mg twice daily by os for 21 days (Group V)
Number of subjects: 30
Study 2551976 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN-beta ser nasal drops (9 X 10(6) units) for 4 weeks
Number of subjects: 325
Study 2551976 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN-beta ser nasal drops (24 X 10(6) units) for 25 days
Number of subjects: 325
Study 2551976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study 319973 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytarabine
Number of subjects: 91
Study 319973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 31525515 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy screening
Number of subjects: 338477
Study 31076942 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated fish oil only
Number of subjects: 60
Study 31076942 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated fish oil in combination with evening primrose oil
Number of subjects: 60
Study 31076942 — intervention group
Group type: COMPARATOR
Intervention: Control group without supplementation
Number of subjects: 60
Study 29306239 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injection
Number of subjects: 0
Study 29306239 — intervention group
Group type: COMPARATOR
Intervention: Blind injection
Number of subjects: 0
Study 25524913 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% Intralipid at 100 mL/h
Number of subjects: 7
Study 25524913 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 7
Study 23483989 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat (LF) diet
Number of subjects: 8
Study 23483989 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate (VLC) diet
Number of subjects: 8
Study 23483989 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic index (LGI) diet
Number of subjects: 8
Study 23483989 — intervention group
Group type: COMPARATOR
Intervention: Control (standard hypocaloric diet)
Number of subjects: 8
Study 21226576 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin‐clavulanate
Number of subjects: 291
Study 21226576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study 19528363 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine-based regimen
Number of subjects: 720
Study 19528363 — intervention group
Group type: COMPARATOR
Intervention: Atenolol-based regimen
Number of subjects: 720
Study 17309405 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly active antiretroviral therapy (HAART) with at least three effective ARVs from at least two different drug classes
Number of subjects: 0
Study 17309405 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to drug therapy greater than 95%
Number of subjects: 0
Study 17309405 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy, two-drug combinations, sequential ARVs, drug cycling, and treatment interruptions
Number of subjects: 0
Study 15529346 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0
Study 15529346 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study 10647530 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (E)
Number of subjects: 15
Study 10647530 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 15
Study 9370502 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer assessments by geriatricians and geriatric nurse practitioners
Number of subjects: 313
Study 9370502 — intervention group
Group type: COMPARATOR
Intervention: Process measures assessed by geriatricians and geriatric nurse practitioners
Number of subjects: 313
Study 1552038 — intervention group
Group type: EXPERIMENTAL
Intervention: IMI plus ALP
Number of subjects: 48
Study 1552038 — intervention group
Group type: COMPARATOR
Intervention: IMI plus placebo
Number of subjects: 48
Study 1552038 — intervention group
Group type: COMPARATOR
Intervention: IMI alone
Number of subjects: 48
Study 4009919 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose/amino acids‐630 mOsmol/liter
Number of subjects: 80
Study 4009919 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose/amino acids/fat emulsion‐706 mOsmol/liter
Number of subjects: 80
Study 4009919 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose/amino acids‐882 mOsmol/liter
Number of subjects: 80
Study 4009919 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose/amino acids/fat emulsion‐983 mOsmol/liter
Number of subjects: 80
Study 4009919 — intervention group
Group type: COMPARATOR
Intervention: Concurrent infusion with 20% fat emulsion
Number of subjects: 80
Study 31220146 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring follow-ups
Number of subjects: 50
Study 31220146 — intervention group
Group type: COMPARATOR
Intervention: Hospital monitoring follow-ups
Number of subjects: 50
Study 28878035 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard regimen (3 × 500 mg Ca/d)
Number of subjects: 990
Study 28878035 — intervention group
Group type: COMPARATOR
Intervention: Low-dose regimen (2 × 500 mg Ca/d)
Number of subjects: 990
Study 28878035 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 990
Study 24493560 — intervention group
Group type: EXPERIMENTAL
Intervention: Total facial nerve decompression (surgery group)
Number of subjects: 24
Study 24493560 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (control group)
Number of subjects: 24